Date: 2015-08-05
Type of information: Licensing agreement
Compound: tivozanib (N-{2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N´-(5-methyl-3-isoxazolyl) urea hydrochloride monohydrate)
Company: Aveo Oncology (USA - MA) Pharmstandard Group (Russian Federation)
Therapeutic area: Cancer - Oncology
Type agreement: licensing development production manufacturing commercialisation
Action mechanism: kinase inhibitor/tyrosine kinase inhibitor. Tivozanib is an oral, potent, selective inhibitor of vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) with a long half-life and activity against all three VEGF receptors.
Disease: all indications excluding ocular conditions
Details: * On August 5, 2015, Aveo Oncology announced that it has entered into an exclusive license agreement with a subsidiary of Pharmstandard Group, the largest Russian pharmaceutical group, for the development, manufacturing and commercialization of AVEO’s small molecule vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor tivozanib in the territories of Russia, Ukraine and the Commonwealth of Independent States (CIS), for all indications excluding ocular conditions.
Financial terms: Under the terms of the agreement, Pharmstandard is obligated to pay Aveo an upfront payment of $1.5 million. Aveo is also eligible to receive up to $7.5 million in connection with the first marketing authorization of tivozanib in Russia, $3.0 million for each additional approved indication thereafter and a high single-digit royalty on net sales in the above mentioned territories. Pharmstandard will be responsible for all activities and costs associated with the further development, regulatory filings, health services and commercialization of tivozanib in the specified territories. A percentage of all upfront, milestone and royalty payments received by Aveo are due to Kyowa Hakko Kirin as a sublicensing fee.
Latest news:
